Zydus Lifesciences Limited — Updates, 10-03-2025: Press Release

Zydus Lifesciences Limited has received final approval from the USFDA to manufacture Ketoconazole Shampoo, 2%, a key antifungal treatment for dandruff and other skin conditions. This product will be produced at Zydus' manufacturing facility in Changodar, Ahmedabad, and enters a market with annual sales of USD 68.89 million in the United States, according to IQVIA data from January 2025. With this latest approval, Zydus now holds a total of 418 approvals out of 483 ANDAs filed since FY 2003-04. This significant development enhances Zydus' product portfolio and positions the company for potential growth in the US market. Investors should watch closely for the impact of this approval on Zydus' revenue streams.